Cochrane · systematic review · CD014201
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
Olasupo, OO, Lowe, MS, Krishan, A, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 11.1%Low 7 · 77.8%Moderate 1 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison of two prophylaxis regimens
Population: children or adults with hemophilia A or B
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of joint bleeding episodes per year (AJBR) | no estimate extracted | 3 studies · 219 participants | Low Downgraded: risk of bias, imprecision |
Number of total bleeds per year (ABR) | no estimate extracted | 7 studies · 310 participants | Low Downgraded: risk of bias, imprecision |
Treatment‐related adverse events | no estimate extracted | 3 studies · 223 participants | Very low Downgraded: risk of bias, imprecision |
Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation
Population: children or adults with hemophilia A
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
AJBR Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation | no estimate extracted | 1 study · 143 participants | Low Downgraded: risk of bias |
ABR Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation | no estimate extracted | 1 study · 143 participants | Low Downgraded: risk of bias |
Any reported adverse effects Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation | no estimate extracted | 1 study · 143 participants | Low Downgraded: risk of bias |
Prophylaxis regimen versus on‐demand treatment
Population: children and adults with haemophilia A or B
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of joint bleeding episodes or joint bleeding frequency Prophylaxis regimen vs on‐demand treatment | no estimate extracted | 2 studies · 164 participants | Low Downgraded: risk of bias, inconsistency |
Number of total bleeds per year or bleeding frequency Prophylaxis regimen vs on‐demand treatment | no estimate extracted | 2 studies · 164 participants | Low Downgraded: risk of bias, inconsistency |
Any reported adverse events Prophylaxis regimen vs on‐demand treatment | RR 1.71 [1.24, 2.37] | 2 studies · 131 participants | Moderate Downgraded: risk of bias, inconsistency |